SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo

Cancer Letters

Volumn 355, Issue 2, 2014, Pages 297-309

  Xia, Yong ^a   Lei, Qian ^a   Zhu, Yongxia ^a   Ye, Tinghong ^a   Wang, Ningyu ^a   Li, Guobo ^a   Shi, Xuanhong ^a   Liu, Yantong ^a   Shao, Bin ^a   Yin, Tao ^a   Zhao, Lifeng ^a   Wu, Wenshuang ^a   Song, Xuejiao ^a   Xiong, Ying ^a,b   Wei, Yuquan ^a   Yu, Luoting ^a  

^a SICHUAN UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti cancer; Apoptosis; Cell cycle arrest; Drug discovery; SKLB316

Indexed keywords

2 CHLORO N (2 (2 (5 CHLOROPYRIDIN 2 YLAMINO) 2 OXOETHYLTHIO)BENZO[D]THIAZOL 6 YL)ACETAMIDE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CASPASE 9; CHECKPOINT KINASE 2; CYCLIN A2; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN E; DOXORUBICIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC25C; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CDC25C PROTEIN, HUMAN; CYCLINE; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CFPAC 1 CELL LINE; COLORECTAL CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; OXIDATIVE STRESS; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TOXICITY TESTING; TREATMENT DURATION; UPREGULATION; ANIMAL; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOTHIAZOLES; CASPASE 9; CDC2 PROTEIN KINASE; CDC25 PHOSPHATASES; CELL PROLIFERATION; CHECKPOINT KINASE 2; COLORECTAL NEOPLASMS; CYCLINS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HCT116 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908209813     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.042     Document Type: Article

References (46)

1. Siegel R., DeSantis C., Jemal A. Colorectal cancer statistics. CA Cancer J. Clin 2014, 64(2014):104-117.
2. Wang C.-C., Li J. An update on chemotherapy of colorectal liver metastases. World J. Gastroenterol 2012, 18:25.
3. Klein A.P. Identifying people at a high risk of developing pancreatic cancer. Nat. Rev. Cancer 2013, 13:66-74.
4. Azmi A. Molecular Diagnostics and Treatment of Pancreatic Cancer: Systems and Network Biology Approaches 2014, Elsevier.
5. Sun L., Mathews L.A., Cabarcas S.M., Zhang X., Yang A., Zhang Y., et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells 2013, 31:1454-1466.
6. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
7. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
8. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol 2005, 23:9408-9421.
9. Zhao B.L., Ma Y., Xu Z.L., Wang J.Z., Wang F.J., Wang D.W., et al. Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways. Cancer Lett 2014, 347:79-87.
10. Chen M.C., Chen C.H., Liu Y.N., Wang H.P., Pan S.L., Teng C.M. TW01001, a novel piperazinedione compound, induces mitotic arrest and autophagy in non-small cell lung cancer A549 cells. Cancer Lett 2013, 336:370-378.
11. Stephenson J.J., Nemunaitis J., Joy A.A., Martin J.C., Jou Y.-M., Zhang D., et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer 2014, 83:219-223.
12. Turner N., André F., Loibl S., Ro J., Iwata H., Harbeck N., et al. Abstract OT3-2-10: phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy. Cancer Res 2013, 73(24 Suppl.):OT3-2-10.
13. Prystowsky M., Feeney K., Kawachi N., Montagna C., Willmott M., Wasson C., et al. Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G(2) delay and mitotic defects. Sci. Rep 2013, 3:2640.
14. Kang T.W., Choi S.W., Yang S.R., Shin T.H., Kim H.S., Yu K.R., et al. Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule. Sci. Rep 2014, 4:5546.
15. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000, 407:810-816.
16. Kok S.H.L., Gambari R., Chui C.H., Yuen M.C.W., Lin E., Wong R.S.M., et al. Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. Bioorg. Med. Chem 2008, 16:3626-3631.
17. Hutchinson I., Chua M.-S., Browne H.L., Trapani V., Bradshaw T.D., Westwell A.D., et al. Antitumor benzothiazoles. 14. 1 synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl) benzothiazoles. J. Med. Chem 2001, 44:1446-1455.
18. Shi X.-H., Wang Z., Xia Y., Ye T.-H., Deng M., Xu Y.-Z., et al. Synthesis and biological evaluation of novel benzothiazole-2-thiol derivatives as potential anticancer agents. Molecules 2012, 17:3933-3944.
19. Wang J.C., Jiang Z., Xiang L.P., Li Y.F., Ou M.R., Yang X., et al. Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis. Sci. Rep 2014, 4:5056.
20. Cappella P., Gasparri F., Pulici M., Moll J. A novel method based on click chemistry, which overcomes limitations of cell cycle analysis by classical determination of BrdU incorporation, allowing multiplex antibody staining. Cytometry A 2008, 73:626-636.
21. Ye T., Xiong Y., Yan Y., Xia Y., Song X., Liu L., et al. The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model. PLoS ONE 2014, 9:e85887.
22. Zheng Y., Zhao Y.-L., Deng X., Yang S., Mao Y., Li Z., et al. Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis. Cancer Invest 2009, 27:286-292.
23. Cao D., Han X., Wang G., Yang Z., Peng F., Ma L., et al. Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents. Eur. J. Med. Chem 2013, 62:579-589.
24. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
25. Liu Y., Wang W., Fang B., Ma F., Zheng Q., Deng P., et al. Anti-tumor effect of germacrone on human hepatoma cell lines through inducing G2/M cell cycle arrest and promoting apoptosis. Eur. J. Pharmacol 2013, 698:95-102.
26. Camidge D.R. Cell cycle-associated kinases as targets for therapy in lung cancer. J. Thorac. Oncol 2010, 5:S461-S462.
27. Fung T.K., Ma H.T., Poon R.Y. Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor. Mol. Biol. Cell 2007, 18:1861-1873.
28. Diaz-Moralli S., Tarrado-Castellarnau M., Miranda A., Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther 2013, 138:255-271.
29. Gong D., Ferrell J.E. The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol. Biol. Cell 2010, 21:3149-3161.
30. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
31. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signal 2009, 11:777-790.
32. Wang Z., Shi X.-H., Wang J., Zhou T., Xu Y.-Z., Huang T.-T., et al. Synthesis, structure-activity relationships and preliminary antitumor evaluation of benzothiazole-2-thiol derivatives as novel apoptosis inducers. Bioorg. Med. Chem. Lett 2011, 21:1097-1101.
33. Wang Y., Decker S.J., Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G checkpoint and induces apoptosis. Cancer Biol. Ther 2004, 3:305-313.
34. Wu W., Ye H., Wan L., Han X., Wang G., Hu J., et al. Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo. Carcinogenesis 2013, 34:1636-1643.
35. Fletcher L., Cheng Y., Muschel R.J. Abolishment of the Tyr-15 inhibitory phosphorylation site on cdc2 reduces the radiation-induced G2 delay, revealing a potential checkpoint in early mitosis. Cancer Res 2002, 62:241-250.
36. Yam C.H., Fung T.K., Poon R.Y.C. Cyclin A in cell cycle control and cancer. Cell. Mol. Life Sci 2002, 59:1317-1326.
37. Hutchins J.R., Clarke P.R. Many fingers on the mitotic trigger. Cell Cycle 2004, 3:41-45.
38. Nyberg K.A., Michelson R.J., Putnam C.W., Weinert T.A. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet 2002, 36:617-656.
39. Chen Y.-N.P., Sharma S.K., Ramsey T.M., Jiang L., Martin M.S., Baker K., et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4325-4329.
40. Zhang W., Konopleva M., Ruvolo V., McQueen T., Evans R., Bornmann W., et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008, 22:808-818.
41. Mazure N.M., Pouysségur J. Hypoxia-induced autophagy: cell death or cell survival?. Curr. Opin. Cell Biol 2010, 22:177-180.
42. Li G.B., Yang L.L., Xu Y., Wang W.J., Li L.L., Yang S.Y. A combined molecular docking-based and pharmacophore-based target prediction strategy with a probabilistic fusion method for target ranking. J. Mol. Graph. Model 2013, 44:278-285.
43. Jung K.H., Noh J.H., Kim J.K., Eun J.W., Bae H.J., Xie H.J., et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J. Cell. Biochem 2012, 113:2167-2177.
44. Siitonen T., Koistinen P., Savolainen E.-R. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27Kip1 in acute myeloblastic leukemia cells. Leuk. Res 2005, 29:1335-1342.
45. Vidal-Laliena M., Gallastegui E., Mateo F., Martinez-Balbas M., Pujol M.J., Bachs O. Histone deacetylase 3 regulates cyclin A stability. J. Biol. Chem 2013, 288:21096-21104.
46. Yu X.-J., Han Q.-B., Wen Z.-S., Ma L., Gao J., Zhou G.-B. Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett 2012, 322:185-194.